IMARC Group has recently released a new research study titled “Parkinson's Disease Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028”, offers a detailed analysis of the market drivers, segmentation, growth opportunities, trends and competitive landscape to understand the current and future market scenarios.
How big is the parkinson's disease treatment market?
The global parkinson's disease treatment market size reached US$ 4.8 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 6.9 Billion by 2028, exhibiting a growth rate (CAGR) of 5.9% during 2023-2028.
What is parkinson's disease treatment?
Parkinson's disease treatment refers to therapeutic interventions aimed at managing the symptoms and improving the quality of life for individuals affected by this progressive neurological disorder. Characterized by tremors, muscle rigidity, and impaired movement, the treatment approach typically involves a combination of medications, physical therapy, and lifestyle modifications. Medications such as levodopa and dopamine agonists help alleviate motor symptoms, while physical therapy focuses on maintaining mobility and balance. Deep brain stimulation (DBS) is a surgical procedure used for advanced cases to control symptoms. Multidisciplinary care and ongoing monitoring are essential features of Parkinson's disease treatment to tailor interventions to each patient's needs.
Request to Get the Sample Report: https://www.imarcgroup.com/parkinsons-disease-treatment-market/requestsample
What are the growth prospects and trends in the parkinson's disease treatment industry?
One of the key drivers is ongoing research and development in the field of neurology and pharmaceuticals. Pharmaceutical companies and research institutions are continually exploring new treatment options, including novel medications and therapeutic approaches, to address the complexities of Parkinson's disease and improve patient outcomes. Moreover, the present continuous tense sees an increasing focus on personalized medicine and precision therapies.
As our understanding of Parkinson's disease becomes more nuanced, healthcare providers are tailoring treatment plans to individual patients' specific needs and genetic profiles. This personalized approach allows for more targeted and effective treatments, enhancing the overall efficacy of Parkinson's disease management.
Additionally, the growing prevalence of Parkinson's disease worldwide is driving the demand for effective treatments. As the global population ages, the incidence of Parkinson's disease is expected to rise, necessitating the development of more accessible and efficient treatment options to meet the growing healthcare demands of affected individuals.
Furthermore, the ongoing advancements in medical technology are contributing to the market growth of Parkinson's disease treatment. Innovations in neuroimaging, wearable devices, and telemedicine are revolutionizing disease diagnosis and management. These technologies facilitate early detection of Parkinson's disease, enable remote monitoring of patients, and provide valuable data for personalized treatment strategies.
Another crucial driver is the increasing awareness and advocacy efforts for Parkinson's disease. Patient advocacy groups, healthcare organizations, and governments are actively promoting awareness campaigns, education, and research funding to support improved treatment options and better patient care. This heightened awareness is encouraging early diagnosis and intervention, leading to more favourable treatment outcomes. The rising focus on multidisciplinary care and holistic treatment approaches.
Healthcare providers are recognizing the importance of an integrated approach that combines medications, physical therapy, occupational therapy, speech therapy, and psychological support. This comprehensive treatment strategy aims to address not only the motor symptoms but also the non-motor aspects of Parkinson's disease, enhancing patients' overall quality of life.
Moreover, the ongoing collaborations between pharmaceutical companies and academic institutions are driving research and innovation in Parkinson's disease treatment. Partnerships and joint ventures enable the pooling of expertise and resources, leading to the development of cutting-edge therapies and potential disease-modifying treatments.
Who are the key players operating in the industry?
The report covers the major market players including:
Parkinson's Disease Treatment Companies:
- AbbVie Inc.
- Acadia Pharmaceuticals Inc.
- Boehringer Ingelheim International GmbH (C. H. Boehringer Sohn AG & Co. KG)
- Hoffmann-La Roche AG
- GlaxoSmithKline Plc
- Lundbeck A/S
- Merck & Co. Inc.
- Mylan N.V.
- Novartis AG
- Orion Corporation
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries
- Wockhardt Ltd.
Key Market Segmentation:
The report has segmented the market into the following categories:
Breakup by Drug Class:
- Carbidopa/Levodopa
- Dopamine Receptor Agonists
- MAO Inhibitors
- COMT Inhibitors
- Anticholinergics
- Others
Breakup by Route of Administration:
- Oral
- Transdermal
- Subcutaneous
- Intestinal Infusion
- Others
Breakup by Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Breakup by Region:
- North America
- Asia-Pacific
- Europe
- Latin America
- Middle East and Africa
Key Highlights of the Report:
- Market Performance (2017-2022)
- Market Outlook (2023-2028)
- Market Trends
- Market Drivers and Success Factors
- Impact of COVID-19
- Value Chain Analysis
- Comprehensive mapping of the competitive landscape
If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Media Contact:
Company Name: IMARC Group
Contact Person: Elena Anderson
Email: sales@imarcgroup.com
Phone: +1-631-791-1145
Address: 134 N 4th St
City: Brooklyn
State: NY
Country: United States
Website: https://www.imarcgroup.com
